Spatially Fractionated Radiotherapy (GRID) Prior to Standard Neoadjuvant Conventionally Fractionated Radiotherapy for Bulky, High-Risk Soft Tissue and Osteosarcomas: Feasibility, Safety, and Promising Pathologic Response Rates

Radiat Res. 2020 Dec 1;194(6):707-714. doi: 10.1667/RADE-20-00100.1.

Abstract

Spatially fractionated radiotherapy (GRID) has been utilized primarily in the palliative and definitive treatment of bulky tumors. Delivered in the modern era primarily with megavoltage photon therapy, this technique offers the promise of safe dose escalation with potential immunogenic, bystander and microvasculature effects that can augment a conventionally fractionated course of radiotherapy. At the University of Maryland, an institutional standard has arisen to incorporate a single fraction of GRID radiation in large (>8 cm), high-risk soft tissue and osteosarcomas prior to a standard fractionated course. Herein, we report on the excellent pathologic responses and apparent safety of this regimen in 26 consecutive patients.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms / pathology
  • Bone Neoplasms / radiotherapy*
  • Dose Fractionation, Radiation*
  • Feasibility Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy*
  • Osteosarcoma / pathology
  • Osteosarcoma / radiotherapy*
  • Radiotherapy / adverse effects
  • Remission Induction
  • Soft Tissue Neoplasms / pathology
  • Soft Tissue Neoplasms / radiotherapy*
  • Treatment Outcome